demonstrated that combination anti-PD-1 and anti-CTLA-4 therapy had minimal tumor growth impact in vivo in mouse models of 4T1 (breast) and B16-GMCSF (melanoma), but that adding the PI3K-γ selective inhibitor eganelisib to the combination therapy resulted in 30% and 80% complete remissions in each model, respectively (109). Here, PDCD1 is linked to neoplasm.